Changes in Invasive pneumococcal disease caused by Streptococcus pneumoniae Serotype 1 following introduction of PCV10 and PCV13: findings from the PSERENADE Project

Changes in Invasive pneumococcal disease caused by Streptococcus pneumoniae Serotype 1 following introduction of PCV10 and PCV13: findings from the PSERENADE Project

Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST...

Full description

Bibliographic Details
Main Authors:	Bennett, J, Hetrich, MK, Quesada, MG, Scott, J
Other Authors:	PSERENADE Team
Format:	Journal article
Published:	MDPI 2021

Similar Items

Changes in Invasive Pneumococcal Disease Caused by <em>Streptococcus pneumoniae</em> Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
by: Julia C. Bennett, et al.
Published: (2021-03-01)

Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project
by: Maria Garcia Quesada, et al.
Published: (2021-04-01)

Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13: the pneumococcal serotype replacement and distribution estimation (PSERENADE) project
by: Knoll, MD, et al.
Published: (2021)

Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project
by: Maria Deloria Knoll, et al.
Published: (2021-04-01)

Invasiveness potential of pneumococcal serotypes in children after introduction of PCV13 in Blantyre, Malawi
by: Amir Kirolos, et al.
Published: (2023-01-01)

Spread of multidrug resistance in non-PCV13/PCV20 serotypes of Streptococcus pneumoniae: A cross-sectional study ten years after the introduction of pneumococcal conjugate vaccine in Japan
by: Mitsuyo Kawaguchiya, et al.
Published: (2023-12-01)

Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children
by: Catarina Silva-Costa, et al.
Published: (2023-12-01)

Antimicrobial susceptibility and serotype replacement of Streptococcus pneumoniae in children before and after PCV13 introduction in Taiwan
by: Hsiang Huang, et al.
Published: (2023-04-01)

Changes in the serotype distribution of Streptococcus pneumoniae causing otitis media after PCV13 introduction in Spain.
by: María Morales, et al.
Published: (2018-01-01)

A Streptococcus pneumoniae lineage usually associated with pneumococcal conjugate vaccine (PCV) serotypes is the most common cause of serotype 35B invasive disease in South Africa, following routine use of PCV
by: Ndlangisa, KM, et al.
Published: (2022)

Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Maria L. Avila-Aguero, et al.
Published: (2017-07-01)

Serotypes and Clonal Diversity of Streptococcus pneumoniae Causing Invasive Disease in the Era of PCV13 in Catalonia, Spain.
by: Eva Del Amo, et al.
Published: (2016-01-01)

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 2015
by: Gili Regev-Yochay, et al.
Published: (2018-07-01)

Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR).
by: Rania Abu Seir, et al.
Published: (2018-01-01)

Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Javier Nieto Guevara, et al.
Published: (2018-04-01)

Exploring Streptococcus pneumoniae capsular typing through MALDI-TOF mass spectrometry and machine-learning algorithms in Argentina: Identifying prevalent NON PCV13 serotypes alongside PCV13 serotypes
by: Jonathan Zintgraff, et al.
Published: (2023-11-01)

The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination
by: Hans-Christian Slotved, et al.
Published: (2016-11-01)

Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan
by: M. Kawaguchiya, et al.
Published: (2016-01-01)

Serotype Distribution and Antimicrobial Sensitivity Profile of Streptococcus pneumoniae Carried in Healthy Toddlers before PCV13 Introduction in Niamey, Niger.
by: Sani Ousmane, et al.
Published: (2017-01-01)

Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil.
by: Juliana Caierão, et al.
Published: (2014-01-01)

Vaccination status (PCV13) of children with pneumococcal meningitis
by: Seidullayeva, Aliya, et al.
Published: (2020-05-01)

Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
by: Rotem Lapidot, et al.
Published: (2020-05-01)

Genomic Characteristics of Invasive Serotype 1 in New Caledonia Prior to the Introduction of PCV13
by: Mariem Hanachi, et al.
Published: (2020-09-01)

Mastoiditis with Streptococcus pneumoniae serotype 19A in one-dose PCV13 vaccinated three-month-old infant
by: B. Gülhan, et al.
Published: (2019-12-01)

A systematic review about Streptococcus Pneumoniae serotype distribution in children in mainland of China before the PCV13 was licensed
by: Shuang Lyu, et al.
Published: (2017-10-01)

Serotype Distribution and Antimicrobial Susceptibility of Streptococcus pneumoniae in Pre- and Post- PCV7/13 Eras, Taiwan, 2002–2018
by: Chi-Jung Wu, et al.
Published: (2020-10-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
by: Helen L. Stacey, et al.
Published: (2019-03-01)

Serotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease
by: Aleksandra Banaszkiewicz, et al.
Published: (2016-03-01)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.
by: Mark van der Linden, et al.
Published: (2016-01-01)

Pediatric Invasive Pneumococcal Disease Three Years after PCV13 Introduction in the National Immunization Plan—The Continued Importance of Serotype 3
by: Catarina Silva-Costa, et al.
Published: (2021-07-01)

Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan
by: Muhammad Imran Nisar, et al.
Published: (2022-01-01)

Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10
by: Germán Camacho Moreno, et al.
Published: (2020-09-01)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021-04-01)

Co-occurrence of bacteria and viruses and serotype distribution of Streptococcus pneumoniae in the nasopharynx of Tanzanian children below 2 years of age following introduction of the PCV13
by: Matilda Emgård, et al.
Published: (2024-01-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
by: Filippo Ansaldi, et al.
Published: (2020-01-01)

One-step multiplex PCR assay for detecting Streptococcus pneumoniae serogroups/types covered by 13-valent pneumococcal conjugate vaccine (PCV13).
by: Fatma Filiz Coskun-Ari, et al.
Published: (2012-01-01)

Reply to ‘Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10’
by: Javier Nieto Guevara, et al.
Published: (2020-09-01)

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines.
by: Adamos Hadjipanayis, et al.
Published: (2016-01-01)

Global Coverage of Pneumococcal Conjugate Vaccine (PCV) and Serotype Distribution after Receiving Vaccine among Targeted PCV Vaccine Countries: A Systematic Review
by: S Rahmani, et al.
Published: (2020-06-01)

The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010–2019
by: Eiman Mokaddas, et al.
Published: (2021-11-01)